Panida Mathaveechotikul

Panida Mathaveechotikul

Auto-generated profile, based on publicly available information

Panida Mathaveechotikul

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
Yusuke KobayashiYusuke Kobayashi
Yusuke Kobayashi
HKhiroaki komatsu
hiroaki komatsu
MIMasanori Isobe
Masanori Isobe
JMJyoti Meena
Jyoti Meena
CWChia-Sui Weng
Chia-Sui Weng
KUKimio Ushijima
Kimio Ushijima
Kobayashi Y, et al. J Gynecol Oncol. 2022 Nov;34(1):e22. https://doi.org/10.3802/jgo.2023.34.e22

17 October 2026 in Journal of Gynecologic Oncology
Verified
Journal Article
Closed access
CCChuenkamon Charakorn
Chuenkamon Charakorn
SRSasivimol Rattanasiri
Sasivimol Rattanasiri
ALArb-aroon Lertkhachonsuk
Arb-aroon Lertkhachonsuk
PMPanida Mathaveechotikul
Panida Mathaveechotikul
GMGareth J McKay
Gareth J McKay
ATAmmarin Thakkinstian
Ammarin Thakkinstian
While the advantages of laparoscopic surgery (LPS) over open surgery (OPS) for endometrial cancer (EC) have been reported, most evidence comes from high-income countries with limited follow-up periods. To emulate a clinical trial using real-world cohort data to compare the clinical effectiveness, specifically recurrence and mortality rate, between LPS and OPS in patients with apparently early-stage EC. A retrospective cohort study was conducted at a tertiary care hospital in Thailand. Treatment effect models with inverse-probability-weighted regression adjustment were employed to balance patient characteristics between the LPS and OPS groups, and subsequently estimated the treatment effect of LPS relative to OPS. From January 2011 to December 2022, 939 patients underwent surgery for EC. With a median follow-up time of 6.0 years (interquartile range=3.7-8.7), LPS significantly reduced the risk of recurrence and death compared to OPS, with a hazard ratio of 0.21 (95% confidence interval [CI]=0.09, 0.50) for recurrence and 0.42 (95% CI=0.24, 0.75) for death. LPS was significantly associated with longer operative time than OPS (mean difference [MD]=79.37 minutes; 95% CI=63.77-94.98) but showed clear advantages in other surgical outcomes, including reduced blood loss (MDs=-210.59 mL; 95% CI=-235.28, -185.89) and shorter hospital stays (MD=-17.25 hours; 95% CI=-25.67, -8.84). Real-world data from an upper-middle-income country indicated that LPS may provide superior oncologic outcomes, such as reduced recurrence and mortality rates, as well as improve surgical outcomes, including less blood loss and shorter hospital stays, despite a longer operative time.

1 January 2021
Verified
Conference Paper
Open access
PMPanida Mathaveechotikul
Panida Mathaveechotikul
CCChuenkamon Charakorn
Chuenkamon Charakorn
ALArb-aroon Lertkhachonsuk
Arb-aroon Lertkhachonsuk
NLNavamol Lekskul
Navamol Lekskul
SWSarikapan Wilailak
Sarikapan Wilailak
KNKittiphon Nagaviroj
Kittiphon Nagaviroj